InSphero Expands 3D Microtissue Portfolio Through Strategic Agreement with Tessara Therapeutics

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.

The normal and pathophysiological neuronal microtissue platforms developed by Tessara are supported by robust scientific validation and have demonstrated broad applicability, including Alzheimer’s disease and traumatic brain injury. The models replicate key aspects of human neuronal function and architecture, offering an ideal solution for researchers seeking more predictive, scalable, and reproducible alternatives to traditional approaches.

InSphero will initially offer these solutions as a service in partnership with the team at Tessara to ensure optimal execution and data quality, with plans to expand access as demand grows.

“Adding Tessara’s neuronal microtissues to our offering is a major step forward in our strategy to become the reference partner for human-relevant 3D model systems. This collaboration enhances our ability to support customers working on neurotoxicity and neurodegeneration with scientifically sound, scalable solutions”, says Paul Clémençon, Chief Business Officer at InSphero. Dr. Christos Papadimitriou, CEO and Co-Founder of Tessara Therapeutics adds, “We are thrilled to partner with InSphero to bring our neuronal models to a broader audience. Their strong customer relationships and scientific credibility make them an ideal partner to help researchers unlock the full potential of our platform.”

Meet both teams at the MPS Summit 2025, June 9-13, and learn more about their common efforts in 3D in vitro neuronal drug discovery.